The DLX2 Knockout HAP1 Polyclonal Cells product comprises a genetically heterogeneous population of HAP1 near-haploid human cells in which the DLX2 gene has been disrupted via CRISPR/Cas9 genome editing. This polyclonal knockout format provides a mixed pool of loss-of-function alleles, enabling robust bulk and pooled functional analyses without the need for single-cell clone isolation. The use of CRISPR/Cas9-mediated gene disruption creates a versatile loss-of-function model suitable for a wide range of cell-based assays.
HAP1 is a near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia (CML) line, which was isolated from a patient in blast crisis. The near-haploid karyotype, with a single copy of most chromosomes, eliminates the confounding effects of zygosity in genetic studies and facilitates straightforward genotype-phenotype correlations. This feature makes HAP1 a powerful platform for haploid genetic screens, drug target validation, and mechanistic investigations in a leukemia-relevant background.
DLX2 encodes a homeobox-containing transcription factor that plays a fundamental role in embryonic development, particularly in forebrain and craniofacial morphogenesis. DLX2 binds specific DNA sequences to regulate genes essential for neuronal differentiation, limb outgrowth, and patterning of the branchial arches. It functions downstream of multiple developmental signaling cascades, notably the BMP4/BMPR1A/SMAD1, SHH/PTCH1/GLI1, and FGF8/MAPK pathways, and receives modulatory input from WNT ligands. DLX2 physically interacts with co-factors such as DLX1, DLX5, MSX1, and TLE family repressors to orchestrate transcriptional networks. Key downstream targets include the transcription factors DLX5 and DLX6, as well as osteocalcin (BGLAP) and collagen type I (COL1A1), linking DLX2 activity to osteogenic differentiation.
In the HAP1 background, DLX2 disruption impairs the transcriptional programs normally coordinated by this factor, offering a simplified model to dissect its roles in signaling integration and cell fate decisions. The near-haploid nature of HAP1 cells allows researchers to attribute observed phenotypic changes directly to DLX2 loss without the complexity of diploid gene compensation. This model is particularly valuable for investigating the contributions of DLX2 to cancer-related processes, as aberrant expression of DLX2 has been reported in osteosarcoma, glioblastoma, and ovarian cancer. Combined with the haploid genetic screening capabilities of HAP1, the knockout pool enables high-throughput identification of synthetic lethal interactions and pathway dependencies.
Researchers can employ this DLX2 knockout polyclonal cell population in a diverse array of experimental workflows. Transcriptomic profiling by RNA-seq and targeted gene expression analysis via RT-qPCR enable global and specific assessment of DLX2-dependent gene regulation. Protein-level studies using western blotting and immunofluorescence allow detection and localization of DLX2 and pathway components. Chromatin immunoprecipitation (ChIP-qPCR) directly probes DLX2 binding at candidate regulatory regions. The product is ideally suited for haploid genetic screens, particularly those employing CRISPR perturbation libraries to map functional interactions in drug resistance or sensitivity. Flow cytometry facilitates cell sorting to enrich subpopulations for downstream clonal analysis if desired. For further technical details or to discuss customization, please contact Ascent Research.
